Literature DB >> 11414734

A "chimeric" C57l-derived Ly49 inhibitory receptor resembling the Ly49D activation receptor.

I K Mehta1, H R Smith, J Wang, D H Margulies, W M Yokoyama.   

Abstract

Ly49D is a natural killer (NK) cell activation receptor that is responsible for differential mouse inbred strain-determined lysis of Chinese hamster ovary (CHO) cells. Whereas C57BL/6 NK cells kill CHO, BALB/c-derived NK cells cannot kill because they lack expression of Ly49D. Furthermore, the expression of Ly49D, as detected by monoclonal antibody 4E4, correlates well with CHO lysis by NK cells from different inbred strains. However, one discordant mouse strain was identified; C57L NK cells express the mAb 4E4 epitope but fail to lyse CHO cells. Herein we describe a Ly49 molecule isolated from C57L mice that is recognized by mAb 4E4 (anti-Ly49D). Interestingly, this molecule shares extensive similarity to Ly49D(B6) in its extracellular domain, but its cytoplasmic and transmembrane domains are identical to the inhibitory receptor Ly49A(B6), including a cytoplasmic ITIM. This molecule bears substantial overall homology to the previously cloned Ly49O molecule from 129 mice the serologic reactivity and function of which were undefined. Cytotoxicity experiments revealed that 4E4(+) LAK cells from C57L mice failed to lyse CHO cells and inhibited NK cell function in redirected inhibition assays. MHC class I tetramer staining revealed that the Ly49O(C57L)-bound H-2D(d) and lysis by 4E4(+) C57L LAK cells is inhibited by target H-2D(d). The structural basis for ligand binding was also examined in the context of the recent crystallization of a Ly49A-H-2D(d) complex. Therefore, this apparently "chimeric" Ly49 molecule serologically resembles an NK cell activation receptor but functions as an inhibitory receptor. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11414734     DOI: 10.1006/cimm.2001.1786

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  8 in total

1.  The activating Ly49W and inhibitory Ly49G NK cell receptors display similar affinities for identical MHC class I ligands.

Authors:  Brian J Ma; Carla M Craveiro Salvado; Kevin P Kane
Journal:  Immunogenetics       Date:  2014-05-07       Impact factor: 2.846

Review 2.  Natural killer cell immune responses.

Authors:  Wayne M Yokoyama
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

3.  Recognition of a virus-encoded ligand by a natural killer cell activation receptor.

Authors:  Hamish R C Smith; Jonathan W Heusel; Indira K Mehta; Sungjin Kim; Brigitte G Dorner; Olga V Naidenko; Koho Iizuka; Hiroshi Furukawa; Diana L Beckman; Jeanette T Pingel; Anthony A Scalzo; Daved H Fremont; Wayne M Yokoyama
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

Review 4.  Unifying concepts of MHC-dependent natural killer cell education.

Authors:  Julie M Elliott; Wayne M Yokoyama
Journal:  Trends Immunol       Date:  2011-07-13       Impact factor: 16.687

5.  Structural variation of the mouse natural killer gene complex.

Authors:  D A Higuchi; P Cahan; J Gao; S T Ferris; J Poursine-Laurent; T A Graubert; W M Yokoyama
Journal:  Genes Immun       Date:  2010-09-23       Impact factor: 2.676

6.  Activation of natural killer cells and dendritic cells upon recognition of a novel CD99-like ligand by paired immunoglobulin-like type 2 receptor.

Authors:  Ikuo Shiratori; Kouetsu Ogasawara; Takashi Saito; Lewis L Lanier; Hisashi Arase
Journal:  J Exp Med       Date:  2004-02-16       Impact factor: 14.307

7.  The ly49 gene family. A brief guide to the nomenclature, genetics, and role in intracellular infection.

Authors:  Alan Rowe Schenkel; Luke C Kingry; Richard A Slayden
Journal:  Front Immunol       Date:  2013-04-16       Impact factor: 7.561

8.  Continuous engagement of a self-specific activation receptor induces NK cell tolerance.

Authors:  Sandeep K Tripathy; Peter A Keyel; Liping Yang; Jeanette T Pingel; Tammy P Cheng; Achim Schneeberger; Wayne M Yokoyama
Journal:  J Exp Med       Date:  2008-07-07       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.